DK3914599T3 - Ikke-immunosuppressive FK506-analoger og anvendelse deraf - Google Patents
Ikke-immunosuppressive FK506-analoger og anvendelse deraf Download PDFInfo
- Publication number
- DK3914599T3 DK3914599T3 DK20746065.0T DK20746065T DK3914599T3 DK 3914599 T3 DK3914599 T3 DK 3914599T3 DK 20746065 T DK20746065 T DK 20746065T DK 3914599 T3 DK3914599 T3 DK 3914599T3
- Authority
- DK
- Denmark
- Prior art keywords
- immunosuppressive
- analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795700P | 2019-01-23 | 2019-01-23 | |
| PCT/US2020/014699 WO2020154455A1 (en) | 2019-01-23 | 2020-01-23 | Non-immunosuppressive fk506 analogs and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3914599T3 true DK3914599T3 (da) | 2025-01-20 |
Family
ID=71735821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20746065.0T DK3914599T3 (da) | 2019-01-23 | 2020-01-23 | Ikke-immunosuppressive FK506-analoger og anvendelse deraf |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12662493B2 (da) |
| EP (2) | EP3914599B1 (da) |
| JP (1) | JP7634880B2 (da) |
| KR (1) | KR102950186B1 (da) |
| CN (2) | CN119751235A (da) |
| AU (1) | AU2020211994B2 (da) |
| CA (1) | CA3127613A1 (da) |
| DK (1) | DK3914599T3 (da) |
| ES (1) | ES2997240T3 (da) |
| IL (1) | IL285085B2 (da) |
| MX (2) | MX2021008824A (da) |
| WO (1) | WO2020154455A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12594275B2 (en) * | 2019-02-07 | 2026-04-07 | The Regents Of The University Of California | Immunophilin binding agents and uses thereof |
| JP2026525902A (ja) * | 2023-07-10 | 2026-08-04 | メドレジェン,リミティド ライアビリティ カンパニー | 経路のダウンレギュレーションおよびアップレギュレーション方法 |
| WO2026059989A1 (en) * | 2024-09-10 | 2026-03-19 | Montara Therapeutics, Inc. | Peripheral blockers for central nervous system-selective drug activity |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991013889A1 (en) * | 1990-03-13 | 1991-09-19 | Fisons Plc | Immunosuppressive macrocyclic compounds |
| GB9014136D0 (en) * | 1990-06-25 | 1990-08-15 | Fujisawa Pharmaceutical Co | Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same |
| US5284877A (en) | 1992-06-12 | 1994-02-08 | Merck & Co., Inc. | Alkyl and alkenyl macrolides having immunosuppressive activity |
| MY110603A (en) | 1993-05-27 | 1998-08-29 | Novartis Ag | Tetrahydropyran derivatives |
| US6811773B1 (en) | 1993-12-22 | 2004-11-02 | Human Genome Sciences, Inc. | Human monocyte colony inhibitory factor (M-CIF) polypeptides |
| EP1127140A2 (en) | 1998-11-06 | 2001-08-29 | President And Fellows Of Harvard College | Fk506-based regulation of biological events |
| WO2000067776A1 (en) | 1999-05-11 | 2000-11-16 | Ortho-Mcneil Pharmaceuticals, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| NZ524421A (en) | 2000-09-15 | 2005-02-25 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
| EP1487795B1 (en) | 2001-09-12 | 2010-11-03 | Anormed Inc. | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings |
| AU2006206525A1 (en) | 2005-01-20 | 2006-07-27 | Array Biopharma Nc. | Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases |
| US10813917B2 (en) * | 2009-12-11 | 2020-10-27 | Medregen, Llc | Treatment methods utilizing stem cell mobilizers and immunosuppressive agents |
| EP3974831A1 (en) | 2010-10-22 | 2022-03-30 | T2 Biosystems, Inc. | Methods for detecting the presence of a bacterium in a whole blood sample |
| WO2015106283A1 (en) * | 2014-01-13 | 2015-07-16 | Amplyx Pharmaceuticals, Inc. | Antifungal compounds |
| CA3043575A1 (en) * | 2016-11-10 | 2018-05-17 | Novartis Ag | Bmp potentiators |
| ES3024357T3 (en) * | 2017-02-17 | 2025-06-04 | Purdue Research Foundation | Targeted ligand-payload based drug delivery for cell therapy |
-
2020
- 2020-01-23 CN CN202411953070.9A patent/CN119751235A/zh active Pending
- 2020-01-23 KR KR1020217026390A patent/KR102950186B1/ko active Active
- 2020-01-23 WO PCT/US2020/014699 patent/WO2020154455A1/en not_active Ceased
- 2020-01-23 JP JP2021543343A patent/JP7634880B2/ja active Active
- 2020-01-23 AU AU2020211994A patent/AU2020211994B2/en active Active
- 2020-01-23 US US17/424,441 patent/US12662493B2/en active Active
- 2020-01-23 DK DK20746065.0T patent/DK3914599T3/da active
- 2020-01-23 EP EP20746065.0A patent/EP3914599B1/en active Active
- 2020-01-23 MX MX2021008824A patent/MX2021008824A/es unknown
- 2020-01-23 IL IL285085A patent/IL285085B2/en unknown
- 2020-01-23 EP EP24208670.0A patent/EP4474014B1/en active Active
- 2020-01-23 ES ES20746065T patent/ES2997240T3/es active Active
- 2020-01-23 CN CN202080022171.8A patent/CN113614091B/zh active Active
- 2020-01-23 CA CA3127613A patent/CA3127613A1/en active Pending
-
2021
- 2021-07-22 MX MX2024006177A patent/MX2024006177A/es unknown
-
2026
- 2026-03-27 US US19/631,744 patent/US20260226075A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119751235A (zh) | 2025-04-04 |
| EP3914599A4 (en) | 2022-10-19 |
| KR20210129058A (ko) | 2021-10-27 |
| MX2021008824A (es) | 2021-10-13 |
| CN113614091B (zh) | 2025-01-17 |
| KR102950186B1 (ko) | 2026-04-07 |
| IL285085B2 (en) | 2025-03-01 |
| US20260226075A1 (en) | 2026-08-06 |
| AU2020211994A1 (en) | 2021-08-12 |
| US20220251108A1 (en) | 2022-08-11 |
| EP4474014A2 (en) | 2024-12-11 |
| EP3914599A1 (en) | 2021-12-01 |
| US12662493B2 (en) | 2026-06-23 |
| JP7634880B2 (ja) | 2025-02-25 |
| WO2020154455A1 (en) | 2020-07-30 |
| AU2020211994B2 (en) | 2025-08-14 |
| EP4474014A3 (en) | 2025-02-26 |
| EP4474014B1 (en) | 2026-07-29 |
| IL285085B1 (en) | 2024-11-01 |
| CA3127613A1 (en) | 2020-07-30 |
| IL285085A (en) | 2021-09-30 |
| JP2022518555A (ja) | 2022-03-15 |
| ES2997240T3 (en) | 2025-02-14 |
| EP3914599B1 (en) | 2024-11-27 |
| CN113614091A (zh) | 2021-11-05 |
| MX2024006177A (es) | 2024-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282487A (en) | Tyk2 inhibitors and uses thereof | |
| IL284835A (en) | Pharmaceutical combination comprising tno155 and ribociclib | |
| IL285178A (en) | Compounds and uses thereof | |
| DK3727426T3 (da) | Incretinanaloger og anvendelser deraf | |
| IL282090A (en) | Tyk2 inhibitors and uses thereof | |
| IL286248A (en) | Tyk2 inhibitors and uses thereof | |
| DK3658557T3 (da) | Tyk2-inhibitorer og anvendelser deraf | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| IL292692A (en) | Mrgprx2 antagonists and uses thereof | |
| IL284799A (en) | Tyk2 inhibitors and uses thereof | |
| DK3813946T3 (da) | Rapamycin-analoger og anvendelser deraf | |
| DK3922266T3 (da) | Toll-like-receptor-7- eller -8-agonist-kolesterolkompleks og anvendelse deraf | |
| EP3885406A4 (en) | Composition and stretched body | |
| IL283942A (en) | Tubulysins and protein-tubulysin conjugates | |
| EP4026846A4 (en) | Anti-tigit immunosuppressant and application thereof | |
| IL291217A (en) | Usp30 inhibitors and uses thereof | |
| IL276877A (en) | Compstatin analogs and their medical uses | |
| HUE063120T2 (hu) | LRRC33-inhibitorok és alkalmazásuk | |
| DK3892621T3 (da) | Haloallylaminforbindelser og anvendelse deraf | |
| DK3650456T3 (da) | Oprensningsmiddel til sukkerkæde eller glycopeptid og anvendelse deraf | |
| EP3743412A4 (en) | GLUCOPYRANOSYL DERIVATIVE AND USE OF IT | |
| DK3919498T6 (da) | Pyrrolopyrimidinderivat og anvendelse deraf | |
| DK4034535T3 (da) | Aza-quinolinforbindelser og anvendelser deraf | |
| PT4077317T (pt) | Tieniloxazolonas e análogos | |
| EP3784948C0 (en) | INFLATABLE STENT |